Truist Securities Maintains Buy on Genmab, Lowers Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Buy rating on Genmab (NASDAQ:GMAB) but lowered the price target from $53 to $50.
September 09, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has maintained a Buy rating on Genmab but reduced the price target from $53 to $50, indicating a slightly less optimistic outlook.
The maintenance of a Buy rating suggests continued confidence in Genmab's performance, but the lowered price target indicates a tempered outlook. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100